Novel therapeutic agents for B-cell lymphoma: Developing rational combinations

Craig B. Reeder, Stephen Maxted Ansell

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Several novel targeted therapies have recently emerged as active in the treatment of non-Hodgkin lymphoma, including small molecules that inhibit critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor microenvironment. Other new agents target novel cell surface receptors or promote DNA damage. Although most of these drugs have single-agent activity, none have sufficient activity to be used alone. This article reviews the utility and potential role of these new agents in the treatment of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.

Original languageEnglish (US)
Pages (from-to)1453-1462
Number of pages10
JournalBlood
Volume117
Issue number5
DOIs
StatePublished - Feb 3 2011

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Cells
Critical Pathways
Tumor Microenvironment
Cell Surface Receptors
DNA Damage
Therapeutics
Pharmaceutical Preparations
Tumors
Molecules
DNA

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Novel therapeutic agents for B-cell lymphoma : Developing rational combinations. / Reeder, Craig B.; Ansell, Stephen Maxted.

In: Blood, Vol. 117, No. 5, 03.02.2011, p. 1453-1462.

Research output: Contribution to journalArticle

@article{b1a9977c00c64709952f5cfd9df0b4c3,
title = "Novel therapeutic agents for B-cell lymphoma: Developing rational combinations",
abstract = "Several novel targeted therapies have recently emerged as active in the treatment of non-Hodgkin lymphoma, including small molecules that inhibit critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor microenvironment. Other new agents target novel cell surface receptors or promote DNA damage. Although most of these drugs have single-agent activity, none have sufficient activity to be used alone. This article reviews the utility and potential role of these new agents in the treatment of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.",
author = "Reeder, {Craig B.} and Ansell, {Stephen Maxted}",
year = "2011",
month = "2",
day = "3",
doi = "10.1182/blood-2010-06-255067",
language = "English (US)",
volume = "117",
pages = "1453--1462",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Novel therapeutic agents for B-cell lymphoma

T2 - Developing rational combinations

AU - Reeder, Craig B.

AU - Ansell, Stephen Maxted

PY - 2011/2/3

Y1 - 2011/2/3

N2 - Several novel targeted therapies have recently emerged as active in the treatment of non-Hodgkin lymphoma, including small molecules that inhibit critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor microenvironment. Other new agents target novel cell surface receptors or promote DNA damage. Although most of these drugs have single-agent activity, none have sufficient activity to be used alone. This article reviews the utility and potential role of these new agents in the treatment of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.

AB - Several novel targeted therapies have recently emerged as active in the treatment of non-Hodgkin lymphoma, including small molecules that inhibit critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor microenvironment. Other new agents target novel cell surface receptors or promote DNA damage. Although most of these drugs have single-agent activity, none have sufficient activity to be used alone. This article reviews the utility and potential role of these new agents in the treatment of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=79551623391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551623391&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-06-255067

DO - 10.1182/blood-2010-06-255067

M3 - Article

C2 - 20978267

AN - SCOPUS:79551623391

VL - 117

SP - 1453

EP - 1462

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -